Advertisement

Seaside Therapeutics Inc. has begun a Phase 3 clinical study of STX209, the company’s treatment for fragile X syndrome, the most common cause of autism. 

The study will look first at the effects of STX209 on social impairment in adults and adolescents between 12 and 25 years old, followed by a second study on children ages 5 to 11. The trial, taking place at 20 sites in the U.S. and enrolling 120 patients, will test the safety, tolerability and efficacy of STX209, whereby social withdrawal will be the measure for efficacy.

SOURCE

Advertisement
Advertisement